• 목록
• 게시판 리스트 옵션
  • 수정
  • 삭제

Ott MP: Neuropathy development in Charcot-Marie-Tooth disease kind 1A. Neurology 2008, 70:378?eighty three. 119. Garcia A, Combarros O, Calleja J, Berciano J: Charcot-Marie-Tooth disorder variety 1A with 17p duplication in infancy and early childhood: a longitudinal scientific and electrophysiologic Lenvatinib review. Neurology 1998, fifty:1061?067. one hundred twenty. Padua L, Pareyson D, Aprile I, Cavallaro T, Quattrone A, Rizzuto N, Vita G, Tonali P, Schenone A: All-natural historical past of CMT1A such as QoL: A 2-year prospective study. Neuromuscul Disord 2008, 18:199?03. 121. Manfioletti G, Ruaro ME, Del Sal G, Philipson L, Schneider C: A advancement arrest-specific (gasoline) gene codes to get a membrane protein. Mol Mobile Biol 1990, ten:2924?930. 122. Choi BO, Koo SK, Park MH, Rhee H, Yang SJ, Choi KG, Jung SC, Kim HS, Hyun YS, Nakhro K, Lee HJ, Woo HM, Chung KW: Exome sequencing is surely an efficient device for genetic screening of Charcot-Marie-Tooth disease. Hum Mutat 2012, 33:1610?615. 123. Kohl B, Groh J, Wessig C, Wiendl H, Kroner A, Martini R: Deficiency of evidence for a pathogenic purpose of T-lymphocytes within an animal product for CharcotMarie-Tooth disease 1A. Neurobiol Dis 2010, 38:78?four. 124. Kohl B, Fischer S, Groh J, Wessig C, Martini R: MCP-1/CCL2 Modifies Axon Homes within a PMP22-Overexpressing Mouse Design for Charcot-MarieTooth 1A Neuropathy. Am J Pathol 2010, 176:1390?399. PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/12711626 125. Ramaglia V, Tannemaat MR, De Kok M, Wolterman R, Vigar MA, King RH, Morgan BP, Baas F: Enhance inhibition accelerates regeneration in the design of peripheral nerve injuries. Mol Immunol 2009, forty seven:302?09. 126. Ramaglia V, Wolterman R, De Kok M, Vigar MA, Wagenaar-Bos I, King RH, Morgan BP, Baas F: Soluble enhance receptor 1 protects the peripheral nerve from early axon decline right after personal injury. Am J Pathol 2008, 172:1043?052. 127. Sereda MW, Meyer Zu Horste G, Suter U, Uzma N, Nave KA: Therapeutic administration of progesterone antagonist inside a design of Charcot-MarieTooth illness (CMT-1A). Nat Med 2003, 9:1533?537. 128. Meyer Zu Horste G, Prukop T, Liebetanz D, Mobius W, Nave KA, Sereda MW: Antiprogesterone treatment uncouples axonal reduction from demyelination inside of a transgenic rat model of CMT1A neuropathy. Ann Neurol 2007, 61:sixty one?2. 129. Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M: Ascorbic acid procedure corrects the phenotype of the mouse product of Charcot-Marie-Tooth ailment. Nat Med 2004, 10:396?01. a hundred thirty. Verhamme C, De Haan RJ, Vermeulen M, Baas F, De Visser M, Van Schaik IN: Oral substantial dose ascorbic acid treatment method for one calendar year in youthful CMT1A individuals: a randomised, double-blind, placebo-controlled stage II demo. BMC Med 2009, 7:70. 131. Micallef J, Attarian S, Dubourg O, Gonnaud PM, Hogrel JY, Stojkovic T, Bernard R, Jouve E, Pitel S, Vacherot F, Remec JF, Jomir L, Azabou E, AlMoussawi M, Lefebvre MN, Attolini L, Yaici S, Tanesse D, Fontes M, Pouget J, Blin O: Outcome of ascorbic acid in individuals with Charcot-Marie-Tooth sickness variety 1A: a multicentre, randomised, double-blind, placebocontrolled demo. Lancet Neurol 2009, eight:1103?110. 132. Burns J, Ouvrier RA, Yiu EM, Joseph PD, Kornberg AJ, Fahey MC, Ryan MM: Ascorbic acid for Charcot-Marie-Tooth disease style 1A in children: a randomised, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/9547713 double-blind, placebo-controlled, safety and efficacy demo. Lancet Neurol 2009, eight:537?forty four. 133. Pareyson D, Reilly MM, Schenone A, Fabrizi GM, Cavallaro T, Santoro L, Vita G, Quattrone A, Padua L, Gemignani F, Visioli F, Laur?M, Radice D, Calabrese D, Hughes RA, Solari A: Asc.